Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve Quarterly Results and any other ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Ltd has informed BSE that its Board of Directors will meet on Thursday, 13 November 2025. The key agenda is to consider and approve the un-audited standalone and consolidated financial results for Q2 and the half-year ended 30 September 2025. The filing is made under Regulation 29(1) of the SEBI Listing Obligations and Disclosure Requirements, 2015. The trading window for designated persons and their immediate relatives is already closed and will remain so until 48 hours after results are declared.
No direct impact on shareholders at this stage. Investors should watch the upcoming Q2 FY26 results declaration on 13 November for the company's actual financial performance.